The new coronavirus 2019 (COVID-19) was declared a pandemic by the World Health Organization
(WHO), due to the alarming levels of spread, severity and inaction. Dealing with COVID-19
must be done on different fronts, such as mitigation, treatment and prevention. Therefore,
strategies and therapies that can help reduce the COVID-19 rate of contamination are still
important alternatives at this time of the pandemic.
The Advanced Penetration Technology™ (APT™) is intellectual property owned by Patient Focused
Tele-Health, LLC, a Rockwall, Texas based company. The company's focus is improving
over-the-counter (OTC) topical formulations, allowing consumers better therapeutic outcomes
with non-prescription medications.
The Advanced Penetration Technology™ (APT™) is a patent-pending, proprietary transdermal dual
carrier formulation. This formulation provides improved dermal penetration and efficacy of
topical API's. Additionally, the APT™ imparts both a mechanical and biochemical effect on the
microbe/fungal cell walls providing a highly effective method of destruction of microbes.
These unique properties impart the broad spectrum anti-viral capability to the APT™
Tetracycline 3% formulation, breaking barriers in pharmacology and virology.
The topical formulation APT™ Tetracycline 3% formulation (APT ™ T3X), is a FDA registered,
Non-Prescription product. This formulation is used in an off label manner as an intranasal
application for prevention of COVID-19 and other viruses. The APT™ T3X as a topical
application will penetrate through and into the mucus layer and deeper. This barrier of
coverage will provide a mitigation effect to decrease the viral load of exposure and
infection. The efficacy of APT™ T3X is due to disrupting the lipid envelope in seconds, hence
neutralizing the virus.
Previous tests were performed with APT™ T3X and the results found were promising. However,
these tests were performed only in vitro and clinical studies demonstrating the ability of
the APT™ T3X to decrease viral exposure and contamination by COVID-19 are necessary to
confirm the possible prophylactic effect, allowing the formulation to be widely distributed
to the general population.
Therefore, the aim of this project is to evaluate the efficacy of the APT™ T3X compared to
placebo to decrease COVID-19 contamination rate in humans.